Related by context. All words. (Click for frequent words.) 79 combination REOLYSIN R 75 Combination REOLYSIN R 68 combination REOLYSIN 65 Phase Ib II 63 Phase IIIb clinical 62 initiated Phase Ib 62 phase IIb clinical 61 Clinical Trial Investigating REOLYSIN 61 Chris Tilly IGN 61 Knebworth Herts SG3 6RR 61 Phase Ib clinical 61 BRIM3 60 Phase #b/#a clinical 60 recurrent malignant glioma 60 multicenter Phase II 60 Phase IIIb 60 GetGoal Phase III 60 RESTORE CLI trial 60 Initiate Phase 60 novel VDA molecule 59 Phase 1b clinical trials 59 Wiley Chichester 59 alvespimycin 59 APEX PD 59 Pivotal Phase III 59 telomerase inhibitor drug 59 Try BetClic 59 ThermoDox ® clinical 59 Completes Patient Enrollment 59 ThermoDox R 59 KOEI maintains 59 monoclonal antibody conjugated 59 Bayer HealthCare Onyx Pharmaceuticals 59 multicenter Phase 59 Phase Ia 59 SUCCEED trial 58 Rob Burman IGN 58 Phase 2b Clinical Trial 58 TASKi2 58 R sorafenib tablets 58 Cloretazine ® 58 biliary tract cancer 58 Phase Ib IIa 58 BRIM2 58 APPRAISE 58 phase Ib 58 LUX Lung 58 imetelstat GRN#L 58 refractory metastatic colorectal cancer 58 Amrubicin 58 Phase 1b clinical 58 Randomized Phase II 58 PROVENGE ® 58 Commences Phase 58 IIb clinical trial 58 Successfully Completes Phase 58 Phase Ib 58 Pivotal Study 58 AIMM trial 57 Aplidin 57 Brentuximab Vedotin SGN 57 Phase IIb III 57 phase IIa 57 phase IIIb 57 phase IIb study 57 Hsp# Inhibitor 57 Orlando Parfitt IGN 57 EOquin TM 57 Initiates Phase II 57 Phase III Clinical Trial 57 tramiprosate Alzhemed TM 57 recurrent NSCLC 57 PROSTVAC ® 57 oral ridaforolimus 57 registrational Phase 57 Pivotal Trial 57 Hedgehog Pathway Inhibitor 57 REOLYSIN ® 57 Commence Phase 57 Phase IIb Trial 57 dose escalation clinical 57 oral deforolimus 57 telomerase therapeutic 57 Phase III ThermoDox 57 COMFORT II 57 IIa clinical trial 57 phase IIb trial 57 FOLOTYN ® 57 phase IIa clinical 57 NO# [002] 57 dose escalation Phase 57 TG MV 57 Confirmatory Phase 57 Pivotal Phase 57 PHASE III 57 Harry Palmin President 57 mitogen activated ERK kinase 56 Modrenal R 56 'S DARLING 56 VEGFR2 inhibitor 56 BIIB# 56 candidate AQ4N 56 CYT# potent vascular disrupting 56 rALLy clinical trial 56 Phase IIb trials 56 Pivotal Phase II 56 Xeloda ® 56 lintuzumab SGN 56 fallopian tube cancers 56 multicenter phase 56 BrachySil ™ 56 MAGE A3 ASCI 56 multicenter randomized Phase 56 oral picoplatin 56 IIa trial 56 Achieves Primary Endpoint 56 including eniluracil ADH 56 receptor tyrosine kinase inhibitor 56 Phase III pivotal 56 phase IIb 56 LymphoStat B TM 56 MKC# MT 56 phase Ib clinical 56 refractory chronic lymphocytic 56 Phase lll 56 XL# anticancer compounds 56 randomized controlled Phase 56 INSPIRE Trial Phase III 56 Exherin 56 ZACTIMA 56 RECORD1 56 Quinamed 56 adecatumumab MT# 56 evaluating Prochymal 56 Clinical Trial Results 56 ALSYMPCA 56 GVAX R 56 ANCHOR trial 56 EXPLORE Xa 56 Exherin TM 56 Prostate AdenoCarcinoma Treatment 56 intratumoural 56 OvaRex ® MAb 56 phase IIb III 55 Zemiva ™ 55 Proellex TM 55 dependent kinase inhibitor 55 Phase 1b Clinical Trial 55 miconazole Lauriad R 55 confirmatory Phase III 55 Annamycin 55 LE SN# 55 Meets Primary Endpoint 55 trastuzumab DM1 T DM1 55 ADVANCE PD 55 Biopharmaceuticals AG 55 PDX pralatrexate 55 Phase 2a Trial 55 Hassan Mirza Gay.com 55 UPLYSO 55 TELINTRA R 55 BrachySil TM 55 PROTECT AF 55 LymphoStat B belimumab 55 ELACYT 55 Randomized Phase 55 PREOS R 55 Xanafide 55 Sapacitabine 55 EGFR expressing mCRC 55 Allovectin 7 55 Metastatic Melanoma 55 Efficacy Results 55 YONDELIS 55 sarcoma melanoma 55 registrational 55 Emma Boyes GameSpot 55 BR.# 55 Cloretazine R 55 Phase IIb Clinical Trial 55 Dacogen injection 55 acyclovir Lauriad R 55 Phase IIb clinical 55 AKT inhibitor 55 Phase 1b trial 55 CRLX# 55 IMA# 55 TASKi3 55 Antony Savvas Computerworld 55 Darinaparsin 55 candidates Dyloject TM 55 G#DT 55 randomized controlled multicenter 55 randomized Phase III 55 GVAX ® 55 evaluating tivozanib 55 3 registrational trial 55 XL# XL# XL# 55 Onyx Pharmaceuticals Announces 55 Anh Nguyen Computerworld 55 ALN VSP Phase 55 hypoxia activated prodrug 55 assessing T DM1 55 histamine dihydrochloride 55 ENDEAVOR III 54 Immunotherapeutic 54 multicenter Phase III 54 ® bortezomib 54 CD# CEA 54 Trial Evaluating 54 forodesine 54 Tom Espiner ZDNet 54 Telatinib 54 placebo controlled Phase 54 ENRICH trial 54 randomized Phase IIb 54 Aryplase 54 PI3K/Akt pathway inhibitor 54 IMPACT IMmunotherapy 54 treatment naive genotype 54 LibiGel Phase III 54 ongoing Phase 1b 54 axitinib 54 Phase 2b 54 IL# PE#QQR 54 TNFerade TM 54 Phase 2b kidney transplant 54 MIVI III 54 MEZAVANT R 54 IMPACT DCM 54 OvaRex R 54 evaluating picoplatin 54 recurrent metastatic ovarian cancer 54 Sucampo Pharma Europe 54 ritonavir boosted danoprevir 54 pralatrexate injection folate analogue 54 cetuximab Erbitux 54 Omacetaxine 54 Tectin TM 54 initiated Phase 1b 54 budesonide foam 54 LEVADEX ™ 54 Ceflatonin R 54 dose escalation trial 54 mertansine 54 Panzem R NCD 54 Curaxin CBLC# 54 trastuzumab Herceptin R 54 HuMax EGFr 54 Phase 1b 54 selectin antagonist 54 Nasdaq ALTH 54 evaluating T DM1 54 catheter occlusion 54 IIa Clinical Trial 54 Phase 2a trial 54 Nasdaq NYMX 54 ospemifene 54 fidaxomicin Phase 54 lumiliximab 54 treatment naïve genotype 54 metastatic HRPC 54 Phase Ib clinical trials 54 Completes Enrollment 54 SNT MC# 54 confirmatory pivotal 54 By Chris Dziadul 54 MIST II 54 PANVAC VF 54 FOLFOX6 chemotherapy regimen 54 HGS ETR1 mapatumumab 54 Phase #/#a trial 54 evaluating satraplatin 54 VNP#M 54 Phase III randomized controlled 54 Phase IIIb study 54 interferon gamma 1b 54 CLARITY study 54 Circ Pharma 54 adjuvant GIST 54 evaluating Xcytrin 54 Testosterone MDTS ® 54 Zemiva TM 54 initiate Phase IIb 54 Dose Ranging Study 54 agonistic human 54 HCV SPRINT 54 Drug Eluting Stent System 54 ATL# [001] 54 Initiates Phase 53 randomized Phase 2b 53 antibody MAb 53 doxorubicin Transdrug ® 53 randomized discontinuation trial 53 demonstrated antitumor activity 53 Glufosfamide 53 AAG geldanamycin analog 53 dirucotide MBP# 53 Inc. Nasdaq ALTH 53 limiting toxicity DLT 53 CUSTOM III 53 relapsed refractory multiple myeloma 53 pivotal Phase 53 BLA filing 53 unique alkylating agent 53 cisplatin gemcitabine 53 STRIDE PD 53 hGH CTP Phase 53 FORTIS M 53 Phase III Trial 53 CRMD# 53 Phase III multicenter 53 refractory acute myeloid 53 Genasense ® 53 Aflibercept 53 MAA submission 53 multicenter randomized controlled 53 pancreatic prostate 53 Syncria albiglutide 53 Multicenter Phase 53 GRAVITAS trial 53 ARRY # 53 metastatic castration resistant 53 Phase III Trials 53 metaglidasen 53 Phase III clinical 53 By Robert Briel 53 AQ4N 53 Microplasmin 53 rALLy trial 53 Phase III psoriasis 53 Initiated Phase 53 evaluating carfilzomib 53 SYMMETRY trial 53 Phase IIb trial 53 RE SURGE 53 BCIRG 53 R roscovitine CDK cyclin 53 Genasense ® oblimersen 53 PrevOnco ™ 53 Initiate Phase II 53 Aurora kinase inhibitor 53 Alzhemed TM 53 dasatinib Sprycel ® 53 initiate Phase 1b 53 Phase 2b trial 53 vidofludimus 53 Personalized Immunotherapy 53 Phase III Pivotal 53 Phase 2b Study 53 EVIZON TM squalamine lactate 53 XL# SAR# 53 virus HCV protease inhibitor 53 TEMSO 53 Phase 2a clinical 53 acyclovir Lauriad ® 53 Romidepsin 53 PSMA ADC 53 Phase 1a clinical 53 Panzem NCD 53 generation purine nucleoside 53 Hepatocellular Carcinoma HCC 53 evaluating Actimmune 53 HGS ETR2 53 huC# DM4 53 Ophena TM 53 non nucleoside HCV 53 pivotal Phase III 53 Canvaxin 53 Myocet 53 oral methylnaltrexone 53 Phase III TRIST 53 palifosfamide Zymafos TM 53 BLP# Liposome Vaccine 53 TransVax ™ 53 Phase IIa clinical 53 oncolytic virus therapies 53 Fodosine 53 registrational trial 52 Advaxis Phase 52 eniluracil 52 Reolysin 52 Phase IIa trial 52 Second Pivotal Phase 52 tiuxetan 52 Phase IIB clinical 52 ruxolitinib 52 trastuzumab DM1 52 EGFR HER2 52 liposomal formulation 52 Allovectin 7 r 52 Ophena 52 metastatic GIST 52 Archexin 52 blinded randomized placebo controlled 52 Phase Ib study 52 Kamada AAT 52 Bezielle 52 carcinoma HCC 52 phase 2a 52 PRESEPT 52 pivotal bioequivalence 52 EFAPROXYN 52 AEG# 52 NUTS code UK 52 Phase 2b clinical 52 BrachySil 52 Initiates Clinical 52 initiate Phase Ib 52 lorcaserin Phase 52 StaphVAX R 52 drug GAP #B# 52 Solazed TM 52 includes TOLAMBA TM 52 metastatic castrate resistant 52 velafermin 52 Azedra TM 52 FOLFIRI chemotherapy 52 Lovaxin C 52 fostamatinib 52 preclinical efficacy 52 Phase 2b clinical trials 52 Phase IIb 52 IAP inhibitor 52 ENDEAVOR IV 52 sorafenib tablets 52 QNEXA ® 52 Phase III 52 Selective Electrochemical Tumor Ablation 52 R bortezomib 52 Pralatrexate 52 PRECISE trial 52 XL# XL# XL# XL# 52 initiate multicenter 52 Aplidin R 52 drug pipeline TAFA# 52 L BLP# 52 Phase 2b randomized 52 Phase #b/#a 52 sapacitabine CYC# 52 IMC #B 52 RELOVAIR ™ 52 initiate Phase 2b 52 TRANSFORMS 52 randomized Phase 52 intravesical infusion therapy 52 crizotinib PF # 52 Dual Opioid 52 SAR# [004] 52 ORENCIA ® 52 TELINTRA 52 Virulizin R 52 Degarelix 52 Fludara ® 52 lead Aganocide compound 52 Sucampo Pharma Ltd. 52 Matrix Phase 2b 52 StemEx 52 HGS ETR1 52 GLP toxicology studies 52 Vidaza ® 52 MBP# dirucotide 52 sunitinib malate 52 Dyloject TM 52 Allovectin 7 R 52 ATTRACT 52 ZYBRESTAT TM 52 Prospective Randomized 52 XIENCE V Stent System 52 fosbretabulin 52 Troxatyl 52 Provecta 52 CE marked PROGENSA 52 PLC ENGLAND WALES 52 Genasense R oblimersen 52 subcutaneous methylnaltrexone 52 Diabetic Macular Edema DME 52 Flutiform ™ 52 multicenter multinational 52 PF # [002] 52 bortezomib Velcade 52 Allovectin 7 ® 52 novel therapeutic antibodies 52 MGd 52 platinum chemotherapeutic 52 MEK inhibitor 52 Study Evaluating 52 multicenter randomized placebo controlled 52 MOZOBIL 52 PEG SN# 52 Receives Marketing Authorization 52 Nasdaq PGNX today 52 zanolimumab 52 depsipeptide 52 Apaziquone 52 eritoran 52 TKB# 52 Urocidin 52 mg/m2 cohort 52 midstage clinical 52 Exelixis compounds 52 Phase 1a 52 TMC# [002] 52 telaprevir dosed 52 Phase IIb clinical trials 52 COSIRA trial 52 pharmacokinetic PK study 52 ara C 52 IgG1 monoclonal antibody 52 low dose cytarabine 52 II Clinical Trial 52 OLpur TM H2H 52 Ossur hf 52 galiximab 52 European Sepsis Trial 52 evaluating bafetinib 52 DASISION 52 Phase IIa trials 52 Ozarelix 51 bavituximab monotherapy trial 51 MEND CABG II 51 PFO migraine 51 docetaxel Taxotere R 51 Pirfenidone 51 PRNewswire FirstCall Genta Incorporated 51 orally administered inhibitor 51 Trastuzumab DM1 51 lenalidomide Revlimid R 51 Phase III randomized 51 Clinical Trial Evaluating 51 next generation URAT1 51 MEND CABG 51 Phase 2b study 51 By Julian Clover 51 Ixempra 51 Zybrestat 51 Antisoma plc LSE 51 BiTE R 51 alpha folate receptor 51 Phase 2a Clinical Trial 51 doublet chemotherapy 51 olaparib 51 oral prodrug 51 Intravenous CP 51 targeted radiotherapeutic 51 prospective multicenter 51 metastatic hormone refractory 51 oral proteasome inhibitor 51 Shigamabs ® 51 TMC# C# 51 FORTIS M trial 51 albiglutide 51 vinorelbine tartrate 51 CHAMPION PCI 51 Onalta ™ 51 PRECISE Trial 51 enzastaurin 51 Azedra 51 Dose Escalation 51 Sulonex TM 51 paclitaxel poliglumex 51 Topical Interferon Alpha 2b 51 Plicera 51 HGS# 51 OwnersDirect.co.uk 51 ALN HPN 51 seliciclib CYC# 51 CG# oncolytic virus 51 PRECISE 51 ISTODAX ® 51 Medidur TM FA 51 vosaroxin 51 Lenocta TM 51 #I TM# 51 inhaled AAT 51 NSABP B 51 PXD# 51 gemcitabine cisplatin 51 Asentar 51 Maximum Tolerated Dose MTD 51 Bioral Amphotericin B 51 2 Limited Ulteo 51 omacetaxine mepesuccinate 51 placebo controlled Phase III 51 2 methoxyestradiol 51 Sorafenib HCC Assessment 51 lintuzumab 51 Phase III Clinical Trials 51 personalized immunotherapy 51 fidaxomicin Phase 3 51 SinuNase TM 51 Alocrest 51 perifosine KRX 51 Civacir 51 trial evaluating PRX# 51 PrevOnco 51 Nasdaq MAPP 51 PEGylated interferon 51 MEK Inhibitor 51 Nexavar ® 51 PEG IFN 51 Exelixis XL# 51 GALNS 51 Pharmos pipeline 51 NUTS code 51 CAMPATH 51 Genz # 51 IRX 2 51 brivaracetam 51 Tumour Vascular Disrupting Agent 51 GATTEX ® 51 dirucotide 51 #:# randomization 51 reslizumab 51 TASQ 51 refractory metastatic 51 confirmatory clinical 51 Aurexis 51 tosedostat 51 Phase III placebo controlled 51 Phenoptin 51 Pre RELAX AHF 51 LEUKINE 51 adecatumumab 51 ZK EPO 51 Diabetic Macular Edema 51 Harrier GR.7s 51 investigational immunotherapy 51 oral JAK#/JAK# inhibitor 51 ThermoDox ® 51 LibiGel ® 51 REVIVE Diabetes 51 CLIRS trial 51 DEB# 51 KSP inhibitor 51 multicenter clinical 51 Trofex 51 compound INCB# 51 PLK1 SNALP 51 Cloretazine R VNP#M 51 novel histone deacetylase 51 Germany Linotype Mt 51 OncoGel 51 Antisoma PLC 51 pharmacodynamic PD 51 ZEVALIN ® 51 Centres LinkedIn 51 BST CarGel R 51 AVADO 51 dose escalation 51 leading oral taxane 50 Phase 2b Trial 50 anticancer compound 50 CINTREDEKIN BESUDOTOX 50 COSTAR II 50 Raptiva ® 50 Voreloxin 50 Insegia 50 HCV RESPOND 2 50 Pivotal Trials 50 DCVax ® Brain 50 RH1 50 LBH# 50 tolevamer 50 TOCOSOL Paclitaxel 50 Multiple Ascending Dose 50 cetuximab Erbitux R 50 product platforms AZX# 50 CR# vcMMAE 50 Clolar ® 50 RSD# oral 50 Multiferon 50 Phase 2a 50 neratinib 50 Phase III ALLEGRO 50 Fx #A 50 candidate Liposomal Grb 50 ganetespib 50 maximally tolerated dose 50 controlled multicenter Phase 50 radiation sensitizer 50 dose dose escalation 50 TAXUS Element Stent System 50 Spectris plc 50 ToGA 50 TLK# 50 married Philip Mountbatten 50 EGS# 50 Phase #b/#a trial 50 EDEMA3 50 Marketing Authorization Application MAA 50 Phase IIa Clinical Trial 50 NeoLipid R 50 Isolagen Process 50 GOUT 50 Taxotere chemotherapy 50 Sudhir Agrawal D.Phil 50 mGluR5 negative 50 BIBW 50 romidepsin 50 Tanespimycin 50 StemEx R 50 Ceflatonin 50 randomized multicentre 50 refractory multiple myeloma 50 HER2 positive metastatic breast 50 Tarceva TM 50 Albuferon Phase 50 GRNVAC1 50 Phase IIa clinical trials 50 ARDIS 50 isoform selective 50 oral rivaroxaban 50 Cloretazine 50 Vicriviroc 50 PREVAIL 50 ABL inhibitor 50 ONCASPAR 50 Phase 2a Study 50 Phase III HEAT 50 TLR9 agonists 50 Vandetanib 50 BEMA TM Fentanyl 50 ANYARA 50 alfa 2a 50 PNP inhibitor 50 IIa clinical trials 50 recombinant PSMA vaccine 50 investigational pan BCR 50 Xcytrin R 50 Phase #/#a 50 UVIDEM 50 RGB # 50 multicenter dose escalation 50 bardoxolone 50 TransMID 50 platinum refractory 50 dose cohort 50 Efficacy Trial 50 histone deacetylase inhibitor 50 sorafenib Nexavar ® 50 modified glutathione analog 50 randomized multicenter Phase III 50 OMP #M# 50 SAR# [002] 50 tubulin inhibitor 50 cutaneous T 50 LEP ETU 50 confirmatory Phase 3 50 CoFactor 50 lorvotuzumab mertansine 50 evaluating mipomersen 50 investigational monoclonal antibody 50 apaziquone 50 DCVax R Brain 50 Fast Tracked Phase 50 Prosidion Limited 50 Oglemilast 50 TRACON Pharmaceuticals Inc. 50 selective immunoproteasome inhibitor 50 Time GMT +0 50 JAK2 inhibitor 50 DSMB recommended 50 Genasense R 50 3 STYLESENSE stores 50 generation URAT1 inhibitor 50 BENLYSTA ® 50 Belinostat 50 Testosterone MDTS R 50 amrubicin 50 ACTEMRA TM 50 Gliadel Wafer 50 Phase IIB 50 Bicifadine 50 Cetrorelix 50 RADIANT 50 EPT Disclosure BHP Billiton 50 Phase III confirmatory 50 Medicsight PLC 50 Onalta 50 sNDA submission 50 Nasdaq OPTR 50 investigational humanized monoclonal antibody 50 COU AA 50 prospective randomized multicenter 50 EndoTAG 50 ILLUMINATE 50 Multicenter Randomized 50 AZILECT ® 50 Urocidin TM 50 MEK inhibitors 50 R Bortezomib 49 systemic ALCL 49 AZX# Phase 49 MBP# [001] 49 Diamyd ® 49 TG# [001] 49 THR beta agonist 49 Enzastaurin 49 Zenvia ™ 49 EVEREST II 49 Feasibility Trial 49 randomized #:#:# 49 immunosuppressive compound 49 Neuradiab 49 Kosan dependence 49 nab paclitaxel 49 docetaxel Taxotere ® 49 aflibercept VEGF Trap 49 refractory indolent non 49 Vitaxin 49 Neulasta ® 49 TKM PLK1 49 delay bone metastases 49 CCR5 mAb 49 First Patient Dosed 49 Novolimus 49 ridaforolimus 49 cilengitide 49 Tamibarotene 49 cancer neuroendocrine tumor 49 vismodegib 49 Zemplar Capsules 49 JAK inhibitor 49 Corlux 49 Clinical Trial 49 cutaneous T cell 49 Surfaxin LS 49 GRN# 49 lymphoma CTCL 49 Atomic Energy Authority UKAEA 49 Lymphoseek ® 49 HepeX B TM 49 LibiGel testosterone gel 49 ABSORB trial 49 & Accessories Staffordshire 49 IIIA NSCLC 49 TELCYTA 49 vaccines oncolytic virus 49 evaluable patients 49 EmbraceAC 49 GTC recombinant human 49 teduglutide 49 oral sapacitabine 49 CLIRS 49 Elagolix 49 Phase III clinical trials 49 TRISENOX 49 Mitoxantrone 49 INSYS 49 DermaVir Patch 49 trastuzumab emtansine T DM1 49 IIa clinical 49 Marketing Authorization Application 49 CB2 selective receptor agonist 49 velafermin belinostat 49 Protease Inhibitor 49 drug conjugate 49 MDEX Consortium 49 Pharmacokinetic PK 49 Talactoferrin 49 ASA# 49 clinical pharmacology studies 49 tezampanel NGX# 49 MKC# 49 HDAC Inhibitor 49 GATTEX TM 49 Intravenous Human 49 vandetanib 49 aflibercept 49 Randomised 49 refractory cutaneous T 49 Proxinium TM 49 NPC 1C 49 Zenvia Phase III 49 refractory AML 49 PuriCore plc 49 Golimumab 49 Æterna Zentaris 49 PRIMO CABG 49 forodesine HCl 49 REOLYSIN 49 alemtuzumab MS 49 Optos plc 49 TAXUS ATLAS 49 Phase II 49 placebo controlled randomized 49 OncoVEX 49 CCX# B 49 PROSTVAC TM 49 EOquin 49 tanespimycin 49 ALN TTR# 49 London WC1N 49 RCW breast cancer 49 Taxotere ® 49 FavId 49 OncoVEX GM CSF 49 BNC# 49 glufosfamide 49 comparing alemtuzumab 49 paclitaxel Taxol ® 49 VALOR trial 49 PEGylated interferon beta 1a 49 MEK inhibitor RDEA# 49 GV# [001] 49 +#-# Asia 49 refractory CLL 49 Panzem R 49 Basilea Toctino R 49 advanced carcinoid 49 motesanib 49 multicentre 49 Cotara ® 49 deforolimus 49 Daclizumab 49 Vicinium TM 49 double blinded placebo 49 evaluating tesamorelin 49 Inc. Nasdaq VVUS 49 Virulizin ® 49 CEQ# 49 labial herpes 49 AZILECT R 49 PEG PAL 49 EOquin TM phase 49 XL# XL# 49 Nashville TN Pleasanton 49 mapatumumab 49 Locteron ® 49 intranasal delivery 49 prospective multicenter randomized 49 #D#C# 49 BLOOM DM 49 Aptivus ® 49 ALN TTR 49 Triapine R 49 brain metastases originating 49 PRNewswire FirstCall ISTA Pharmaceuticals 49 CLORETAZINE TM VNP#M 49 BioNumerik 49 Elotuzumab 49 PHX# 49 Viramidine 49 Anturol ® 49 recurrent glioblastoma 49 systemic Phase 1b 49 RNAi Therapeutic 49 BRAF inhibitor 49 MVA BN 49 talactoferrin 49 REVIVE TA 49 AIR CF1 49 CBLC# 49 gemcitabine chemotherapy 48 FOLOTYN 48 thorough QT 48 PRTX 48 icatibant 48 rxRNA 48 CYC# 48 commercialize deforolimus 48 PRE SURGE 48 ACCEDE 48 #-# Darkes Lane 48 elotuzumab 48 MERLIN TIMI 48 Phase III metastatic melanoma 48 Nasdaq ISTA 48 tesmilifene 48 Abiraterone acetate 48 Denufosol 48 Androxal TM 48 HCD# [002] 48 severe hypercholesterolemia 48 IMC A# 48 catheter occlusion CO 48 AIR CF2 48 SPIRIT FIRST 48 REOLYSIN R 48 AZX# 48 GED aPC 48 sodium thiosulfate STS 48 bevacizumab Avastin ® 48 APTIVUS 48 Phase IIa 48 cediranib 48 multiple myeloma MM 48 cathepsin K inhibitor 48 Genasense oblimersen sodium Injection 48 ixabepilone 48 Rectogesic 48 investigational hepatitis C 48 antiangiogenesis therapies 48 AIM AMRN 48 blind multicenter 48 prostate cancer AIPC 48 teriflunomide 48 NVA#